13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

Contineum Therapeutics, Inc. CTNM

Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for neuroscience, inflammation and immunology indications. The company has no commercialized products yet and its revenue is meager. The core of its investment analysis is the progress of the pipeline under development and key clinical catalysts. Key risks include continued losses, shareholder dilution and insider reductions.

Sources Company public information simplywall.st
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • Develop small molecule drugs targeting the fields of neuroscience, inflammation and immunology, with all drug candidates currently in the clinical stage.
  • The main indications may include multiple sclerosis, etc. The specific pipeline progress requires attention to the clinical trial data disclosed by the company.

Current key questions

  • The company has not yet achieved revenue (annual revenue is less than US$1 million), continues to rely on financing to support research and development, and its losses are increasing.
  • Shareholders' equity has been significantly diluted due to financing activities in the past year, and earnings per share have fallen at a compound annual rate of 37.1%.
  • Management and insiders have been net selling recently, which may reflect considerations of short-term stock price risk.
  • The stock price is highly volatile (average weekly fluctuation is 11%) and is sensitive to market sentiment. Investors need to pay close attention to pipeline catalysts.
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -13.42% Buyback -21.17%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baker Bros. Advisors 0.1% $18.6M 2026-03-31
HHLR Advisors / Hillhouse Lei Zhang 0.5% $8.7M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 4 13F filing periods
Net reducers 0 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $8.7M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares New +669,337 / 0
HHLR Advisors / Hillhouse Lei Zhang 4 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$4.7M
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +669,337 (New) Total shares 669,337 Value $8.7M

Recent mentions

No public mentions.